PROSCA & BLADDR 2023

 

PROSCA & BLADDR 2023
Avatar

NMIBC & MIBC Data With an Impact on Clinical Practice

By PROSCA & BLADDR 2023 FEATURING Bernadett Szabados
By PROSCA & BLADDR 2023 FEATURING Bernadett Szabados
0 views
January 16, 2024
Comments 0
Login to view comments. Click here to Login
BLADDR
07:53
PROSCA & BLADDR 2023

Future Management of T2N0M0 Urothelial Carcinoma From the Urologist’…

Feat. E. Laukhtina
08:01
PROSCA & BLADDR 2023

Future Management of T2N0M0 Urothelial Carcinoma From the Medical On…

Feat. D. Raggi
11:05
PROSCA & BLADDR 2023

Future Management of T2N0M0 Urothelial Carcinoma From the Pathologis…

Feat. A. Cimadamore
09:24
PROSCA & BLADDR 2023

Future Management of T2N0M0 Urothelial Carcinoma From the Radiation …

Feat. P. Sargos
06:04
PROSCA & BLADDR 2023

Arguments for Using Urinary Biomarkers for the Surveillance of NMIBC

Feat. F. Witjes
08:52
PROSCA & BLADDR 2023

Urinary Biomarkers for the Surveillance of NMIBC: Why the Role of Cy…

Feat. M. Moschini
09:57
PROSCA & BLADDR 2023

Obstacles and Opportunities With Staging, Grading, and Molecular Cla…

Feat. E. Comperat
11:34
PROSCA & BLADDR 2023

Small Cell Neuroendocrine Carcinoma of the Urinary Bladder

Feat. P. Hoskin
10:15
PROSCA & BLADDR 2023

Management of Upper Urinary Tract Carcinoma In Situ

Feat. B. Konety
09:41
PROSCA & BLADDR 2023

Perioperative Systemic Therapies for MIBC

Feat. B. Szabados
09:18
PROSCA & BLADDR 2023

Best Practices for Radical Cystectomy and Urinary Reconstruction

Feat. B. Konety
07:05
PROSCA & BLADDR 2023

Novel Systemic Approaches Towards Bladder Preservation

Feat. B. De Ruiter
11:41
PROSCA & BLADDR 2023

The Role of RT in Bladder Preservation

Feat. X. Maldonado
16:26
PROSCA & BLADDR 2023

High-Risk, BCG-Unresponsive NMIBC Beyond Radical Cystectomy: Intrave…

Feat. F. Guerrero-Ramos
08:08
PROSCA & BLADDR 2023

Response to Bladder Cancer Treatment in Men and Women

Feat. U. Vogl
06:44
PROSCA & BLADDR 2023

Positive Surgical Margins After Radical Cystectomy for MIBC: What’s …

Feat. P. Sargos
06:41
PROSCA & BLADDR 2023

Handling High-Risk Localized UTUC: The Role of Perioperative Treatme…

Feat. I. Durán
04:34
PROSCA & BLADDR 2023

Risk Stratification in NMIBC

Feat. F. Guerrero-Ramos
09:09
PROSCA & BLADDR 2023

Improving the Quality of Tumor Resection in Bladder Cancer

Feat. L. Mertens
10:21
PROSCA & BLADDR 2023

High-Risk NMIBC Beyond Radical Cystectomy: The Role of RT

Feat. V. Achard
12:09
PROSCA & BLADDR 2023

Bladder Cancer Targeted Therapies on the Horizon: All Good or Should…

Feat. P. Grivas
11:47
PROSCA & BLADDR 2023

Dealing With Adverse Events of Targeted Therapies in Bladder Cancer

Feat. R. Jones
09:30
PROSCA & BLADDR 2023

A New SOC in 1L Treatment of mUC?

Feat. I. Durán, D. Castellano
10:38
PROSCA & BLADDR 2023

Best Practices for mUC: Defining & Treating Oligometastatic Blad…

Feat. P. Hoskin
10:37
PROSCA & BLADDR 2023

Treatment Advancements for Intermediate-Risk NMIBC

Feat. J. Irani
08:24
PROSCA & BLADDR 2023

Health-Related QoL After TMT in Bladder Cancer: Translation Into Dai…

Feat. D. Leelamany
11:03
PROSCA & BLADDR 2023

Misconceptions About TMT in Bladder Cancer

Feat. V. Fonteyne
11:56
PROSCA & BLADDR 2023

mUC Data With an Impact on Clinical Practice

Feat. D. De Maeseneer
12:50
PROSCA & BLADDR 2023

NMIBC & MIBC Data With an Impact on Clinical Practice

Feat. B. Szabados